

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal626amd

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA
NEWS	41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT

MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:57:23 ON 22 MAY 2003

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:57:31 ON 22 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAY 2003 HIGHEST RN 518004-10-9
DICTIONARY FILE UPDATES: 20 MAY 2003 HIGHEST RN 518004-10-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNnote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 10039557.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak
G2 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 13:57:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 855493 TO ITERATE

46.8% PROCESSED 400000 ITERATIONS (1 INCOMPLETE) 97 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.26

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 855493 TO 855493
PROJECTED ANSWERS: 164 TO 250

L2 97 SEA SSS FUL L1

=> s l2 and caplus/lc
27939655 CAPLUS/LC

L3 96 L2 AND CAPLUS/LC


=> s l2 not l3

L4 1 L2 NOT L3

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 287407-24-3 REGISTRY
CN D-Valine, N-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-methyl-3-[[2-(4-morpholinyl)ethyl]thio]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H32 N2 O6 S2
CI CDM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
154.45	154.66

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:58:34 ON 22 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2003 VOL 138 ISS 21
FILE LAST UPDATED: 21 May 2003 (20030521/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:57:23 ON 22 MAY 2003)

FILE 'REGISTRY' ENTERED AT 13:57:31 ON 22 MAY 2003

L1	STRUCTURE UPLOADED
L2	97 S L1 FUL
L3	96 S L2 AND CAPLUS/LC
L4	1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 13:58:34 ON 22 MAY 2003

=> s l2

L5 19 L2


=> d 1-19 ibib abs hitstr

L5 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003:174862 CAPLUS
 TITLE: A novel antimicrobial peptide from the sea hare
 Dolabella auricularia
 AUTHOR(S): Iijima, Ryosuke; Kisugi, Jun; Yamazaki, Masatoshi
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Teikyo
 University,
 Tsukui-gun, Kanagawa, 199-0195, Japan
 SOURCE: Developmental & Comparative Immunology (2003), 27(4),
 305-311
 CODEN: DCIMDQ; ISSN: 0145-305X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The sea hare Dolabella auricularia is a marine shell-less gastropod.
 Four cytotoxic glycoproteins named dolabellin A, C, E and P were found in
 the animal previously. An antimicrobial factor was newly isolated from the
 sea hare's body-wall including skin and mucus. This factor is a novel
 peptide which consists of 33 amino acid residues, and is called
 dolabellin B2. Dolabellin B2 was cytotoxically effective against
 some pathogenic microorganisms at a concn. of 2.5-100 .mu.g/mL.
 IT 214596-09-5, Dolabellin B 2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (novel antimicrobial peptide from the sea hare Dolabella auricularia)
 RN 214596-09-5 CAPLUS
 CN L-Glutamine, L-seryl-L-histidyl-L-glutamyl-L-.alpha.-aspartyl-L-
 cysteinyl-L-tyrosyl-L-.alpha.-glutamyl-L-alanyl-L-leucyl-L-histidyl-L-
 lysyl-L-cysteinyl-L-methionyl-L-alanyl-L-seryl-L-histidyl-L-seryl-L-lysyl-
 L-prolyl-L-phenylalanyl-L-seryl-L-cysteinyl-L-seryl-L-methionyl-L-lysyl-L-
 phenylalanyl-L-histidyl-L-methionyl-L-cysteinyl-L-leucyl-L-glutamyl-L-
 glutamyl-L- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
 prepd. by acylation of N-tert-butyl-1,2,3,4,4a(S),5,5,6,7,8,8a(S)-
 decahydro-2-[2(R)-hydroxy-3(S)-[[3-(methanesulfonyl)-L-valyl]amino]-4-
 phenylbutyl]-3(S)-isoquinolinecarboxamide (prepn. given) with
 (3-pyridyloxy)acetic acid trifluoroacetate. The product showed IC50 =
 0.6 and 17 nM in the HIV protease inhibition and antiviral assays, resp.
 IT 431896-46-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of decahydroisoquinolinecarboxamide amino acid derivs. as HIV
 protease inhibitors)
 RN 431896-46-7 CAPLUS
 CN 3-isoquinolinecarboxamide, 2-[(2R,3S)-3-[[[(2R)-2-(2,3-dihydro-2-oxo-1H-
 imidazol-1-yl)-3-methyl-3-(methanesulfonyl)-1-oxobutyl]amino]-2-hydroxy-4-
 phenylbutyl]-N-(1,1-dimethylethyl)decahydro-, (3S,4aS,8aS)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:408652 CAPLUS
 DOCUMENT NUMBER: 136:402024
 TITLE: Preparation of decahydroisoquinoline-3-carboxamide
 amino acid derivatives as HIV protease inhibitors
 INVENTOR(S): Martin, Joseph Armstrong; Redshaw, Sally; Swallow,
 Steven; Thomas, Gareth John
 F. Hoffmann-La Roche A.-G., Switz.
 PATENT ASSIGNEE(S): PCT Int. Appl., 141 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042277	A1	20020530	WO 2001-EPI3068	20011112
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TH, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AS, BY, KG, KE, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002029546	A5	20020603	AU 2002-29546	20011112
US 6472404	B1	20021029	US 2001-999082	20011120
PRIORITY APPL. INFO.:			GB 2000-28483	A 20001122
			WO 2001-EPI3068	W 20011112
OTHER SOURCE(S):			MARPAT 136:402024	
GI				




AB Isoquinolinecarboxamide compds. I [R1 = H, OH or NHR2, where R2 = H, alkyl, alkenyl, alkynyl, arylalkyl, heterocyclylalkyl, cycloalkyl, alkyl- or arylcarbonyl or -sulfonyl, carbamoyl, etc.; R3, R4 = alkyl or R3R4C is a carbocycle; R5 = alkyl, arylalkyl, heterocyclylalkyl or R4 and R5 taken together with the carbon and sulfur atom to which they are attached form a heterocycle; R6 = alkyl, arylalkyl, heterocyclylalkyl, alkyloxyalkyl, hydroxyalkyl, aminoalkyl, fluoroalkyl; R13 = H or the residue of an inorg. or an org. ester; R15 = aryl; with the proviso that if R3, R4 and R5 are Me, R6 is tert-Bu, R13 is H and R15 is Ph, R2 is not benzyloxycarbonyl or 2-quinolinecarbonyl] were prepd. as HIV protease inhibitors. Thus, I (R1 = 3-pyridyloxyacetamido; R3, R4 = Me; R6 = tert-Bu; R13 = H; R15 = Ph) was


L5 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:138069 CAPLUS
 DOCUMENT NUMBER: 136:325889
 TITLE: Synthesis of a New Stable .beta.-Sulfinyl Nitroxide
 and the Corresponding Alkoxyamine for
 Living/Controlled Radical Polymerization of Styrene:
 Kinetic and ESR Studies
 AUTHOR(S): Drockenmüller, Eric; Catala, Jean-Marie
 CORPORATE SOURCE: Institut Charles Sadron, CNRS-ULP, Strasbourg, 67083,
 FR.
 SOURCE: Macromolecules (2002), 35(7), 2461-2466
 CODEN: MAMOBX; ISSN: 0024-9297
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The syntheses of a new nitroxide bearing a sulfoxide group at the .beta.-position (with respect to nitrogen) and the corresponding N-.beta.-sulfinyl alkoxyamine are reported. Styrene was polymd. in bulk in the presence of this new alkoxyamine. The polymn. satisfies the usual criteria of a living-controlled radical polymn., with a linear increase of mol. wt. vs. yield and a const. transient radical concn. with time. However, the polymn. rates were independent of alkoxyamine concn. but higher than the thermal polymn. ones: Rp/Rth = 2.6 at 90 .degree.C, 3.7 at 100 .degree.C, and 3.5 at 110 .degree.C. Kinetic and ESR studies showed that both transient and persistent radical concns. do not follow the corresponding theor. evolutions with time but reach stationary states. The different rate consts. (kd and kc) and corresponding activation energies were estd., showing that the sulfoxide group has a large effect mainly on the combination reaction, the value of which is unusually low for such system (Kc .apprxq. 105 L mol-1 s-1).
 IT 412929-85-2P
 RL: CAT (Catalyst use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (kinetic and ESR study of living controlled radical polymn. of styrene in presence of sulfinyl nitroxide and alkoxyamine)
 RN 412929-85-2 CAPLUS
 CN Nitroxide, 1,1-dimethylethyl
 1-[1-(ethylsulfinyl)ethyl]-2,2-dimethylpropyl
 (9CI) (CA INDEX NAME)



IT 412929-88-5P
 RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (kinetic and ESR study of living controlled radical polymn. of styrene in presence of sulfinyl nitroxide and alkoxyamine)
 RN 412929-88-5 CAPLUS
 CN 3-Pentanamine, N-(1,1-dimethylethyl)-4-(ethylsulfinyl)-2,2-dimethyl-N-(1-phenylethoxy)- (9CI) (CA INDEX NAME)




IT 412929-83-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and oxidn. of)
 RN 412929-83-0 CAPIUS
 CN 3-Pentanamine, N-(1,1-dimethylethyl)-4-(ethylsulfinyl)-N-hydroxy-2,2-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 2001:894331 CAPIUS
 DOCUMENT NUMBER: 137:63447
 TITLE: Michael addition of thiols, carbon nucleophiles and amines to dehydroamino acid and dehydropeptide derivatives
 AUTHOR(S): Ferreira, Paula M. T.; Maia, Hernani L. S.; Monteiro, Luis S.; Sacramento, Joana
 CORPORATE SOURCE: Department of Chemistry, University of Minho, P-4700-320, Port.
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1
 (2001), (23), 3167-3173
 CODEN: JCSPCE; ISSN: 1472-7781
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:63447
 AB Michael addns. of nitrogen heterocycles, thiols, carbon nucleophiles and amines to dehydroalanine deriva., including a glycidyldehydroalanine peptide, are performed in fair to good yields. Didehydroaminobutyric acid

derivs. react only with the stronger nucleophiles but in considerably lower yields and often no reaction is obsd. with the corresponding didehydrophenylalanine derivs. When a tosyl group is bonded to the nitrogen atom of the dehydroamino acid, in some cases the addn. product undergoes elimination of this group and yields the corresponding .beta.-substituted deriv. of the .alpha.,.beta.-didehydroamino acid. Addn. of some beta.-dicarbonyl compds. leads to formation of products to which the structure of .alpha.,.alpha.-disubstituted cyclic amino acid deriva. is assigned.
 IT 439611-99-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of dehydroamino acids or -peptides using Michael addn. to dehydroalanine deriva)
 RN 439611-99-1 CAPIUS
 CN Cysteine, N-benzoyl-N-[1,1-dimethylethoxy]carbonyl]-S-(2-methoxy-2-oxoethyl)-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


ACCESSION NUMBER: 2001:878883 CAPIUS
 DOCUMENT NUMBER: 136:279165
 TITLE: Synthesis of .beta.-sulfinyl nitroxides
 AUTHOR(S): Drockenmüller, Eric; Catala, Jean-Marie
 CORPORATE SOURCE: Institut Charles Sadron, Strasbourg, 67083, Fr.
 SOURCE: Tetrahedron Letters (2001), 42(51), 9011-9013
 CODEN: TETLEA; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The synthesis is reported of .beta.-sulfinyl nitroxides via nucleophilic addn. of .alpha.-lithiated sulfoxides to N-tert-butyl-.alpha.-Ph nitroxide and subsequent copper(II)-catalyzed oxidn. of the .beta.-sulfinyl hydroxylamine intermediate.


IT 406712-83-2P 406712-85-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and copper(II)-catalyzed oxidn. to give .beta.-sulfinyl nitroxide)
 RN 406712-83-2 CAPIUS
 CN Benzenemethanamine, N-(1,1-dimethylethyl)-N-hydroxy-.alpha.-[1-methyl-1-phenylpropyl]sulfinylethyl- (9CI) (CA INDEX NAME)




RN 406712-85-4 CAPIUS
 CN Benzenemethanamine, N-(1,1-dimethylethyl)-N-hydroxy-.alpha.-[1-methyl-1-phenylpropyl]sulfinylethyl- (9CI) (CA INDEX NAME)



IT 406712-88-7P 406712-89-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of .beta.-sulfinyl nitroxides)
 RN 406712-88-7 CAPIUS
 CN Nitroxide, 1,1-dimethylethyl 2-(ethylsulfinyl)-1-phenylpropyl (9CI) (CA INDEX NAME)



RN 406712-89-8 CAPIUS
 CN Nitroxide, 1,1-dimethylethyl 2-methyl-2-[(1-methylethyl)sulfinyl]-1-phenylpropyl (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:821889 CAPLUS
DOCUMENT NUMBER: 136:118295
TITLE: Stereoselective synthesis of .delta.-lactones from 5-oxoalkanals via one-pot sequential acetalization, Tishchenko reaction, and lactonization by cooperative catalysis of samarium ion and mercaptan
AUTHOR(S): Hsu, Jue-Liang; Fang, Jim-Min
CORPORATE SOURCE: Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan
SOURCE: Journal of Organic Chemistry (2001), 66(25), 8573-8584
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB By the synergistic catalysis of samarium ion and mercaptan, a series of 5-oxoalkanals was converted to (substituted) .delta.-lactones in efficient and stereoselective manners. This one-pot procedure comprises a sequence of acetalization, Tishchenko reaction and lactonization. The deliberate use of mercaptan, by comparison with alc., is advantageous to facilitate the catalytic cycle. The reaction mechanism and stereochem. are proposed and supported by some expl. evidence. Such samarium ion/mercaptan cocatalyzed reactions show the feature of remote control, which is applicable to the asym. synthesis of optically active .delta.-lactones. This study also demonstrates the synthesis of two insect pheromones, (2S,5R)-2-methylhexanolide and (R)-hexadecanolide, as examples of a new protocol for asym. redn. of long-chain aliph. ketones.
IT 389837-41-6P 389837-49-4P 389837-52-9P 389837-56-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(one-pot sequential acetalization, Tishchenko reaction, and lactonization by the promotion of samarium ion and mercaptans in stereoselective synthesis of .delta.-lactones from 5-oxoalkanals)
RN 389837-41-6 CAPLUS
CN Benzenemethanethiol, .alpha.-[(1S)-1-(ethylmethylamino)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).




RN 389837-49-4 CAPLUS
CN Acetamide, N-[(1S,2R)-2-mercapto-1-methyl-2-phenylethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).


L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 389837-52-9 CAPLUS
CN Acetamide, N-[(1R,2R)-2-mercapto-1-methyl-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).




RN 389837-56-3 CAPLUS
CN Acetamide, N-[(1R,2S)-2-mercapto-1,2-diphenylethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 104 THERE ARE 104 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2001:636044 CAPLUS
DOCUMENT NUMBER: 135:195495
TITLE: Preparation of 2-oxo-1-pyrrolidine derivatives and their anticonvulsant activity
INVENTOR(S): Differding, Edmond; Kenda, Benoit; Lallemand, Benoit; Matagne, Alain; Michel, Philippe; Pasau, Patrick; Talaga, Patrice
PATENT ASSIGNEE(S): UCB, S.A., Belg.
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2001062726 A2 20010830 WO 2001-EP1992 20010221
WO 2001062726 A3 20020117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NL, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1265862 A2 20021218 EP 2001-925354 20010221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
NO 2002003997 A 20021022 NO 2002-3997 20020822
PRIORITY APPLN. INFO.: GB 2000-4297 A 20000223
WO 2001-EP1992 W 20010221
OTHER SOURCE(S): MARPAT 135:195495
GI



AB The title 2-oxo-1-pyrrolidine deriva. I [X = CAINR5R6, CA1OR7, CA1R8, cyano; A1, A2 = O, S, NR9; R1 = H, alkyl, aryl, CH2R1; R2-R4 = H, halo, OH, SH, etc.; R2a, R3a, R4a = H, halo, alkyl, alkenyl, alkynyl, aryl; R5-R7, R9 = H, OH, alkyl, aryl, heterocyclyl; R8 = H, OH, SH, etc.] were prepd. E.g., (2S)-2-[2-oxo-4-(phenoxymethyl)-1-pyrrolidinyl]butanamide was prepd. I are particularly suited for treating neurol. disorders such as epilepsy.
IT 357337-34-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-oxo-1-pyrrolidine derivs. and their anticonvulsant activity)
RN 357337-34-9 CAPLUS
CN 1-Pyrrolidineacetamide, .alpha.-(1-mercapto-1-methylethyl)-2-oxo-4-propyl- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2001:508661 CAPLUS
DOCUMENT NUMBER: 135:256816
TITLE: A purely synthetic, diversity amenable version of norephedrine thiols for the highly enantioselective diethylzinc addition to aldehydes
AUTHOR(S): Jimeno, Ciri; Moyano, Albert; Pericas, Miquel A.; Riera, Antoni
CORPORATE SOURCE: Unitat Recerca Síntesi Asimètrica, Dep. Quim. Org., Universitat de Barcelona, Barcelona, E-08028, Spain
SOURCE: Synlett (2001), (7), 1153-1157
CODEN: SYNLES; ISSN: 0936-5214
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:256816
AB A new .beta.-amino thiol arising from purely synthetic yet enantiopure amino alcs. has been prepd. and successfully used in the addn. of diethylzinc to arom. aldehydes, yielding secondary alcs. in ee's up to 99%.
IT 361543-72-8P
RL: CAT (Catalyst use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(enantioselective diethylzinc addn. to aldehydes catalyzed by .beta.-amino thiols)
RN 361543-72-8 CAPLUS
CN Ethanethioic acid, S-[(1R,2S)-1-phenyl-2-(1-piperidinyl)-3-(triphenylmethoxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 361543-73-9P 361543-74-0P
RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(enantioselective diethylzinc addn. to aldehydes catalyzed by .beta.-amino thiols)
RN 361543-73-9 CAPLUS
CN Ethanethioic acid, S-[(1R,2S)-2-(diethylamino)-1-phenyl-3-(triphenylmethoxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 361543-74-0 CAPLUS

L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:314178 CAPLUS
DOCUMENT NUMBER: 134:326767
TITLE: Preparation of acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid TACE inhibitors
INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Cole, Derek C.; Du, Mila T.; Laakso, Leif M.
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: U.S., 109 PP.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6225311	B1	20010501	US 2000-492691	20000127
US 2003008849	A1	20030109	US 2000-748912	20000127
PRIORITY APPL. INFO.:			US 1999-155249P	P 19990127
			US 2000-492691	A3 20000127

OTHER SOURCE(S): MARPAT 134:326767
AB Amino acid deriva. HONHCOCRI2NR3-X-Y-Z-CR4R5C.tplbond.CR6 [X = SO2, F(O)R10, where R10 = alkyl, cycloalkyl, aryl, heteroaryl; Y = aryl, heteroaryl, with the proviso that X and Z may not be bonded to adjacent atoms of Y; Z = O, NH, CH2, S; R1 = H, aryl, alkyl, alkenyl, alkynyl; R2 =

any group given for R1, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloheteroalkyl or R1 and R2 may form a ring; R3 = H, alkyl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl or R1 and R3 may form a ring;

R4, R5 = H, alkyl, CN, C.tplbond.CH; R6 = any group given for R1, heteroaryl, cycloalkyl, cycloheteroalkyl or pharmaceutically acceptable salts were prepd. as inhibitors of TNF-.alpha. converting enzyme (TACE). Thus, 2-[(4-but-2-ynyloxybenzenesulfonyl)methylamino]-N-hydroxy-3-methylbutyramide was prepd. and showed IC50 = 7.4 nM for inhibition of TACE.

IT 287404-30-2P 287404-31-3P 287404-33-5P
287404-34-6P 287404-35-7P 287404-36-8P
287404-37-9P 287404-38-0P 287404-39-1P
287404-40-4P 287404-41-5P 287404-42-6P
287404-43-7P 287404-44-8P 287404-45-9P
287404-46-0P 287404-47-1P 287404-48-2P
287404-49-3P 287404-50-4P 287404-51-5P
287404-52-6P 287404-53-7P 287404-54-8P 287404-55-9P
287404-56-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid TACE inhibitors)


RN 287404-30-2 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-morpholinyl)ethyl]thio]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 1-Piperidineethanethiol, .alpha.-phenyl-.beta.-[[triphenylmethoxy]methyl]-, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl


RN 287404-31-3 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-methyl-1-piperazinyl)ethyl]thio]- (9CI) (CA INDEX NAME)




RN 287404-33-5 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[2-(diethylamino)ethyl]thio]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 287404-34-6 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(1-pyrrolidinyl)ethyl]thio]- (9CI) (CA INDEX NAME)




RN 287404-35-7 CAPLUS
CN Butanamide
2-[[[4-(2-butaninyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-
[[2-(1H-imidazol-1-yl)ethyl]thio]-3-methyl- (9CI) (CA INDEX NAME)





RN 287404-37-9 CAPLUS
CN Butanamide,
2-({[4-(2-butinyloxy)phenyl]sulfonyl)methylamino}-N-hydroxy-3-
methyl-3-[[3-(4-morpholinyl)propyl]thio]- (9CI) (CA INDEX NAME)



RN 287404-38-0 CAPLUS
 CN Butanamide,
 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-
 methyl-3-[[3-[4-methyl-1-piperazinyl]propyl]thio]- (9CI) (CA INDEX NAME)




RN 287404-39-1 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[3-(diethylamino)propyl]thio]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 287404-36-8 CAPLUS
CN L-Proline, 1-[2-[[[2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-(hydroxyamino)-1,1-dimethyl-3-oxopropyl]thio]ethyl]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 287404-40-4 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-
methyl-3-(methylthio)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287404-41-5 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-(ethylthio)-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 287404-42-6 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-
methyl-3-(propylthio)- (9CI) (CA INDEX NAME)



RN 287404-43-7 CAPLUS

CN Butanamide,


2-[[[4-(2-butyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-pyridinylmethyl]thio]- (9CI) (CA INDEX NAME)



RN 287404-44-8 CAPLUS

CN Butanamide,

2-[[[4-(2-butyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[phenylmethyl]thio]- (9CI) (CA INDEX NAME)



RN 287408-89-3 CAPLUS

CN Butanamide,

2-[[[4-(2-butyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-methyl-1-piperazinyl)ethyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A




● x HCl

RN 287408-91-7 CAPLUS

CN Butanamide,


2-[[[4-(2-butyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[[2-(1H-imidazol-1-yl)ethyl]thio]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● x HCl

PAGE 2-A




● x HCl

RN 287408-92-8 CAPLUS

CN L-Proline,

1-2-[[[2-[[[4-(2-butyloxy)phenyl]sulfonyl]methylamino]-3-(hydroxyamino)-1,1-dimethyl-3-oxopropyl]thio]ethyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287408-93-9 CAPLUS

CN Butanamide,

2-[[[4-(2-butyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(4-morpholinyl)propyl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 287408-94-0 CAPLUS

CN Butanamide,


2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(4-methyl-1-piperazinyl)propyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 287408-95-1 CAPLUS

CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[3-(diethylamino)propyl]thio]-N-hydroxy-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287408-96-2 CAPLUS

CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[2-(diethylamino)ethyl]thio]-N-hydroxy-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287407-25-4 CAPLUS


CN D-Valine, N-[[[4-(2-butynyloxy)phenyl]sulfonyl]-N-methyl-3-[[2-(4-morpholinyl)ethyl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 287407-24-3

CMF C22 H32 N2 O6 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 287407-26-5 CAPLUS

CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-morpholinyl)ethyl]thio]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 287407-21-0P 287407-22-1P 287407-23-2P

287407-25-4P 287407-26-5P 287407-29-8P

287407-30-1P 287408-52-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid TACE inhibitors)


RN 287407-21-0 CAPLUS

CN D-Valine,

N-[[[4-(2-butynyloxy)phenyl]sulfonyl]-3-[[2-(hydroxyethyl)thio]-N-

methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287407-22-1 CAPLUS


CN D-Valine, 3-[[[2-bromoethyl]thio]-N-[[[4-(2-butynyloxy)phenyl]sulfonyl]-N-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287407-23-2 CAPLUS


CN D-Valine, N-[[[4-(2-butynyloxy)phenyl]sulfonyl]-N-methyl-3-[[2-(4-morpholinyl)ethyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 287407-29-8 CAPLUS

CN D-Valine, N-[[[4-(2-butynyloxy)phenyl]sulfonyl]-N-methyl-3-(methylthio)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287407-30-1 CAPLUS

CN D-Valine, N-[[[4-(2-butynyloxy)phenyl]sulfonyl]-N-methyl-3-(methylthio)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287408-52-0 CAPLUS

CN D-Valine, N-[[[4-(2-butynyloxy)phenyl]sulfonyl]-3-mercapto-N-2-propenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
 REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:283928 CAPLUS
 DOCUMENT NUMBER: 134:310745
 TITLE: Preparation of beta disubstituted metalloprotease inhibitors
 INVENTOR(S): Pikul, Stanislaw; Ohler, Norman Eugene; Solinsky, Kelly Michelle; Almstead, Neil Gregory; De, Biswanath;
 Natchus, Michael George
 PATENT ASSIGNEE(S): Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027084	A1	20010419	WO 2000-US28194	20001012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DO, EE, EG, ES, FI, FR, GB, GD, GE, GH, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014759	A	20020702	BR 2000-14759	20001012
EP 1224171	A1	20020724	EP 2000-970820	20001012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2002001748	A	20020614	NO 2002-1748	20020412
US 1999-159320P P 19991014				
WO 2000-US28194 W 20001012				
OTHER SOURCE(S): MARPAT 134:310745				
GI				



AB Comps. I (R1 = OH, NHOH; R2 = hydrogen, hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo; R3 = hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl; R4 = (CR7CR7')X(CR8CR8')1EA and k = 0-4 and l = 0-4 and each of R7, R7', R8,


L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
 R8' = H, alkyl, alkenyl, alkynyl, aryl, etc. and X = O, S, SO, etc. and E = bond, SO2, NR10, etc. and A = H, alkyl, alkenyl, etc.; R5 = H, alkyl, haloalkyl, etc.; R6 = alkyl, alkenyl, alkynyl, etc.; G = S, O, NR11, etc.;
 Z = cycloalkyl, heterocycloalkyl, etc.), which are inhibitors of metalloproteases, were prepd. E.g., (2R,3S)-2-(4'-methoxybiphenyl-4-sulfonylamino)-3-(4-methylbenzyloxy)-3-thiazol-2-ylpropionic acid was prepd.
 IT 334991-44-SF
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of beta disubstituted metalloprotease inhibitors)
 RN 334991-44-S CAPLUS
 CN D-Phenylalanine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-N-methyl-.beta.-[(3-pyridinylmethyl)thio]-, (.beta.R)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:758683 CAPLUS
 DOCUMENT NUMBER: 134:71128
 TITLE: Applications of Aziridinium Ions. Selective Syntheses of .alpha.,.beta.-Diamino Esters, .alpha.-Sulfanyl-.beta.-amino Esters, .beta.-Lactams, and 1,5-Benzodiazepin-2-one
 AUTHOR(S): Chuang, Tsung-Hsun; Sharpless, K. Barry
 CORPORATE SOURCE: Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
 SOURCE: Organic Letters (2000), 2(23), 3555-3557
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:71128
 AB A variety of nucleophiles, including amines, thiolates, and alkoxides, were employed to open aziridinium ions. The latter are opened stereospecifically and regioselectively at the C-3 position by a wide range of amines, and thiolate nucleophiles attack predominately at the C-2 position. Poor regioselectivities (ca. 1:1) were obsd. using nucleophiles derived from phenols, carboxylic acids, and imides. Base-mediated ring closure of the aziridinium opening products, from primary amines, gave .beta.-lactams and a 1,5-benzodiazepin-2-one in high yields.
 IT 314278-12-1P
 RL: SPN (Synthetic preparation); PREP (Preparation) (ring cleavage of aziridinium ions via reactions with amines, thiolates, and alkoxides)
 RN 314278-12-1 CAPLUS
 CN 4-Morpholinepropanoic acid, .alpha.-[(1,1-dimethylethyl)thio]-.beta.-phenyl-, ethyl ester, (.alpha.R,.beta.R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000-35102 CAPLUS
 DOCUMENT NUMBER: 133:150908
 TITLE: Preparation of acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid TACE inhibitors
 INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Cole, Derek
 Cecill
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: PCT Int. Appl., 293 pp.
 CODEN: PIXK2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044709	A2	20000803	WO 2000-US1981	20000127
WO 2000044709	A3	20001221		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356299	AA	20000803	CA 2000-2356299	20000127
EP 1144368	A2	20011017	EP 2000-905750	20000127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007752	A	20011204	BR 2000-7752	20000127
JP 2002535382	T2	20021022	JP 2000-595966	20000127
NO 2001003674	A	20010924	NO 2001-3674	20010726
BG 105738	A	20020531	BG 2001-105738	20010726
PRIORITY APPLN. INFO.: US 1999-238255 A 19990127 WO 2000-US1981 W 20000127				


OTHER SOURCE(S): MARPAT 133:150908
 AB Amino acid deriva. HOHNCOIRN2R3-X-Y-Z-CR4R5C.tplbond.CR6 [X = SO2, P(O)R10, where R10 = alkyl, cycloalkyl, aryl, heteroaryl; Y = aryl, heteroaryl, with the proviso that X and Z may not be bonded to adjacent atoms of Y; Z = O, NH, CH2, S; R1 = H, aryl, alkyl, alkenyl, alkynyl; R2 =

any group given for R1, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloheteroalkyl or R1 and R2 may form a ring; R3 = H, alkyl, cycloalkyl, cycloheteroalkyl, aralkyl, heteroaralkyl or R1 and R3 may form a ring;
 R4, R5 = H, alkyl, CN, C.tplbond.CH; R6 = any group given for R1, heteroaryl, cycloalkyl, cycloheteroalkyl or pharmaceutically acceptable salts were prepd. as inhibitors of TNF- α converting enzyme (TACE). Thus, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methylbutyramide was prepd. and showed IC50 = 7.4 nM for inhibition of TACE.

IT 287404-30-2P 287404-31-3P 287404-33-5P
 287404-34-6P 287404-35-7P 287404-36-8P
 287404-37-9P 287404-38-0P 287404-39-1P
 287404-40-4P 287404-41-5P 287404-42-6P
 287404-43-7P 287404-44-8P 287404-45-9P
 287404-46-0P 287404-47-1P 287404-48-2P
 287404-49-3P 287404-50-4P 287404-51-5P
 287404-52-6P 287404-53-7P 287404-54-8P


L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
 287404-96-2P 287404-97-3P 287404-98-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) [prepn. of acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid TACE inhibitors]
 RN 287404-30-2 CAPLUS
 CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-morpholinyl)ethyl]thio]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 287404-31-3 CAPLUS
 CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-methyl-1-piperazinyl)ethyl]thio]- (9CI) (CA INDEX NAME)




RN 287404-33-5 CAPLUS
 CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[2-(diethylamino)ethyl]thio]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 287404-34-6 CAPLUS
 CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(1-pyrrolidinyl)ethyl]thio]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 287404-35-7 CAPLUS
 CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(1H-imidazol-1-yl)ethyl]thio]-3-methyl- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 287404-36-8 CAPLUS
 CN L-Proline, 1-(2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-(hydroxyamino)-1,1-dimethyl-3-oxopropyl]thio)ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 287404-37-9 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(4-morpholinyl)propyl]thio]- (9CI) (CA INDEX NAME)




RN 287404-38-0 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(4-methyl-1-piperazinyl)propyl]thio]- (9CI) (CA INDEX NAME)




RN 287404-39-1 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[3-(diethylamino)propyl]thio]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 287404-43-7 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 287404-44-8 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 287408-89-3 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-methyl-1-piperazinyl)ethyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)




RN 287404-40-4 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(4-methyl-1-piperazinyl)propyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287404-41-5 CAPLUS
CN Butanamide, 2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[3-(diethylamino)propyl]thio]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 287404-42-6 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(diethylamino)propyl]thio]- (9CI) (CA INDEX NAME)



●x HCl

RN 287408-90-6 CAPLUS
CN Butanamide,
2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(1-pyrrolidinyl)ethyl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)



PAGE 2-A




● HCl

RN 287408-91-7 CAPLUS

CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[[2-(1H-imidazol-1-yl)ethyl]thio]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 287408-94-0 CAPLUS

CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(4-methyl-1-piperazinyl)propyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 287408-95-1 CAPLUS

CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[3-(diethylamino)propyl]thio]-N-hydroxy-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287408-96-2 CAPLUS

CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-[[2-(diethylamino)ethyl]thio]-N-hydroxy-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A




● HCl

RN 287408-92-8 CAPLUS

CN

L-Proline, 1-[2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-3-(hydroxyamino)-1,1-dimethyl-3-oxopropyl]thio]ethyl-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 287408-93-9 CAPLUS


CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[3-(4-morpholinyl)propyl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 287409-29-4 CAPLUS

CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-[[2-(4-morpholinyl)ethyl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287409-30-7 CAPLUS

CN Butanamide,

2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)




IT 287407-21-OP 287407-22-1P 287407-23-2P

287407-25-4P 287407-26-5P 287407-29-8P


287407-30-1P 287408-52-OP

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (prepn. of acetylenic .alpha.-amino acid-based sulfonamide hydroxamic
 acid TRACE inhibitors)
 RN 287407-21-0 CAPLUS
 CN D-Valine,
 N-[[4-(2-butyloxy)phenyl]sulfonyl]-3-[(2-hydroxyethyl)thio]-N-
 methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 287407-22-1 CAPLUS
 CN D-Valine, N-[[4-(2-bromomethyl)thio]-N-[[4-(2-butyloxy)phenyl]sulfonyl]-N-
 methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 287407-23-2 CAPLUS
 CN D-Valine, N-[[4-(2-butyloxy)phenyl]sulfonyl]-N-methyl-3-[[2-(4-
 morpholinyl)ethyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 287407-25-4 CAPLUS
 CN D-Valine, N-[[4-(2-butyloxy)phenyl]sulfonyl]-N-methyl-3-[[2-(4-
 morpholinyl)ethyl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 CN 1
 CRN 287407-24-3
 CMF C22 H32 N2 O6 S2


L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN D-Valine, N-[[4-(2-butyloxy)phenyl]sulfonyl]-N-methyl-3-(methylthio)-
 (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 287408-52-0 CAPLUS
 CN D-Valine, N-[[4-(2-butyloxy)phenyl]sulfonyl]-3-mercapto-N-2-propenyl-,
 methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 287407-26-5 CAPLUS
 CN Butanamide,
 2-[[[4-(2-butyloxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-
 methyl-3-[[2-(4-morpholinyl)ethyl]thio]-, (2S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 287407-29-8 CAPLUS
 CN D-Valine, N-[[4-(2-butyloxy)phenyl]sulfonyl]-N-methyl-3-(methylthio)-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 287407-30-1 CAPLUS

L5 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:246919 CAPLUS
 DOCUMENT NUMBER: 133:17366
 TITLE: The first successful use of simple
 1,2-aminothioethers
 as hybrid ligands in the palladium-catalyzed
 asymmetric allylic substitution reaction
 AUTHOR(S): Rassias, Gerasimos A.; Page, Philip C. Bulman;
 Reigler, Serge; Christie, Steven D. R.
 CORPORATE SOURCE: Dep. Chem., Loughborough Univ., Loughborough,
 Leicestershire, LE11 3TU, UK
 SOURCE: Synlett (2000), (3), 379-381
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:17366
 GI




AB Phenylmethylisoquinolinylpropanethiol ethers I (R = Ph, 4-MeOC6H4,
 2-naphthyl, Me, Me2CH, Me3C, Ph3C) incorporating 1,2-aminothioethers into
 hybrid sulfide-tertiary amine ligands have been prep'd. and used
 successfully in the palladium-catalyzed asym. allylic substitution
 reaction for the first time. E.g., aminothioether I (R = Me3C) and
 bis(chloro-eta.3-allyl)palladium were stirred in methylene chloride;
 (E)-PRCH:CHCH(OAc)Ph was added, followed by cesium carbonate and di-Me
 malonate; after stirring for 1.5 h, (-)-(S)-II was isolated in 99% yield
 and 72% ee.
 IT 273223-79-3P 273223-80-6P 273223-81-7P
 273223-82-8P
 RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation);
 USES (Uses)
 (prepn. of nonracemic hybrid tertiary amine-thioether ligands for
 palladium-catalyzed enantioselective allylic substitution)
 RN 273223-79-3 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(1R,2S)-1-methyl-2-(methylthio)-2-
 phenylethyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 273223-80-6 CAPLUS


L5 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(1R,2S)-1-methyl-2-[(1-methylethyl)thio]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273223-81-7 CAPLUS
CN Isoquinoline, 2-[(1R,2S)-2-[(1,1-dimethylethyl)thio]-1-methyl-2-phenylethyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273223-82-8 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(1R,2S)-1-methyl-2-phenyl-2-[(triphenylmethyl)thio]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L5 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:671830 CAPLUS

DOCUMENT NUMBER: 132:35935


TITLE: Diastereomeric sulfinates derived from (L)-N-methylephedrine: synthesis, applications and rearrangements
AUTHOR(S): Drabowicz, Jozef; Bujnicki, Bogdan; Biscarini, Paolo; Mikolajczyk, Marian
CORPORATE SOURCE: Centre of Molecular and Macromolecular Studies, Polish

SOURCE: Academy of Sciences, Lodz, 90-363, Pol.
Tetrahedron: Asymmetry (1999), 10(16), 3177-3187
CODEN: TASYE3; ISSN: 0957-4166

PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:35935


AB The reaction of sulfinyl chlorides with (L)-N-methylephedrine alone or in the presence of tertiary amines was found to produce diastereomeric sulfinates with diastereomeric purities up to 90%. The diastereomeric ratio is strongly influenced by the nature of substituents on the sulfinyl chlorides and to some extent by the reaction conditions. In a few cases, the pure diastereomers were isolated by chromatog. and used for the prepn. of optically active sulfoxides. The silica gel catalyzed rearrangement of sulfinates to the corresponding sulfones is also discussed.
IT 252230-36-7P 252230-37-8W 252230-38-9W
252230-39-0P 252230-40-3P 252230-41-4P
RL: SPN (Synthetic preparation): PREP (Preparation)
(diastereomeric sulfinates derived from (L)-N-methylephedrine, synthesis, applications and rearrangements)
RN 252230-36-7 CAPLUS
CN Benzeneethanamine, N,N,.alpha.-trimethyl-.beta.-(methylsulfonyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252230-37-8 CAPLUS
CN Benzeneethanamine, .beta.-(ethylsulfonyl)-N,N,.alpha.-trimethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 252230-38-9 CAPLUS


CN Benzeneethanamine, N,N,.alpha.-trimethyl-.beta.-(propylsulfonyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252230-39-0 CAPLUS
CN Benzeneethanamine, N,N,.alpha.-trimethyl-.beta.-[(1-methylethyl)sulfonyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252230-40-3 CAPLUS
CN Benzeneethanamine, .beta.-(butylsulfonyl)-N,N,.alpha.-trimethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252230-41-4 CAPLUS
CN Benzeneethanamine, .beta.-[(1,1-dimethylethyl)sulfonyl]-N,N,.alpha.-trimethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:497835 CAPLUS
 DOCUMENT NUMBER: 131:350834
 TITLE: Utilization of industrial waste materials. Part 14. Synthesis of .beta.-amino alcohols and thiols with a 2-azabicyclo[3.3.0]octane backbone and their application in enantioselective catalysis
 AUTHOR(S): Kossenjana, Michael; Soeberdt, Michael; Wallbaum, Sabine; Harms, Klaus; Martens, Jürgen; Aurich, Hans-Günter
 CORPORATE SOURCE: Fachbereich Chemie, Universität Oldenburg, Oldenburg, D-26129, Germany
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1999), (16), 2353-2365
 CODEN: JCPRB4; ISSN: 0300-922X
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:350834
 AB New, chiral .beta.-tert-amino tert-alcs. were synthesized from an enantiomerically pure sec-amine via glycine, alanine and phenylglycine derivs. Grignard addns. to these esters provided rigid amino alcs. in fair yields. The abs. configurations of the stereogenic centers, which arose during the alkylation step, were assigned by an independent route leading to some of the optical antipodes. The target compds. were deriva. of cyclopenta[b]pyrrole-1-ethanol and cyclopenta[b]pyrrole-1-ethanethiol. Condensation of enantiomerically pure .beta.-amino alcs. with a .gamma.-keto ester afforded N,O-acetals which were subsequently reduced to the .beta.-tert-amino alcs. X-Ray anal. of one compd. was performed to verify the stereochem. obsd. by chem. correlation. The nucleophilic ring opening of enantiomerically pure styrene oxide by an amine resulted in the formation of regioisomeric amino alcs. Amino thiol derivs. were also prepd. Redn. of these compds. to thiols and subsequent oxidn. afforded amino disulfides. Finally, the bicyclic .beta.-amino alcs. and thiols were used as chiral ligands in the enantioselective addn. of diethylzinc to benzaldehyde and ee values up to 96% were found.
 IT 250371-17-6P 250371-20-1P
 RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (prepn. of cyclopenta[b]pyrrole-1-ethanol and cyclopenta[b]pyrrole-1-ethanethiol derivs. as stereoselective addn. catalysts)
 RN 250371-17-6 CAPLUS
 CN Ethanethioic acid, S-[(1R,2S)-2-[(3aS,6aS)-hexahydrocyclopenta[b]pyrrol-1(2H)-yl]-1-phenylpropyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:745022 CAPLUS
 DOCUMENT NUMBER: 130:24972
 TITLE: Preparation of aryloxybenzenesulfonylhydroxycarboxamides
 INVENTOR(S): es as metalloproteinase inhibitors.
 PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
 SOURCE: Bender, Steven L.
 PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 Patent
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850348	A1	19981112	WO 1998-US9389	19980508
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GU, HR, KE, NE, NI, SN, TD, TG				
AU 9872940	A1	19981127	AU 1998-72940	19980508
US 1992	H1	20010904	US 1999-372064	19990811
PRIORITY APPLN. INFO.: US 1997-45931P P 19970509				
US 1998-73240 B1 19980506				
WO 1998-US9389 W 19980508				

 OTHER SOURCE(S): MARPAT 130:24972
 GI



AB Title compds. [I: Ar = aryl, heteroaryl; X = NHOH, OH; R1 = H, CHR3R4, COR3, cycloalkyl, aryl, heteroaryl; R3, R5 = H, suitable substituent; R4 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R2 = CH2R5, or R5 and R4 = (substituted) C atoms single- or double-bonded to one another], were prepd. Thus, (R)-2-pipecolic acid in CH2Cl2 was treated sequentially with Me3SiCl, Et3N, and 4-(4-bromophenoxy)benzenesulfonyl chloride (prepn. given) in CH2Cl2 to give (R)-1-[4-(4-bromophenoxy)benzenesulfonyl]piperidine-2-carboxylic acid. This in DMF was treated with N-methylmorpholine and BOP and then with NH2OH.HCl and addnl. N-methylmorpholine to give (R)-1-[4-(4-bromophenoxy)benzenesulfonyl]-N-hydroxypiperidine-2-carboxamide. The latter inhibited stromelysin with IC50 = 0.04 nM.
 IT 215921-66-7P 215921-67-8P 215921-68-9P
 215921-69-0P 215921-70-3P 215921-83-8P
 215921-84-8P 215921-85-0P 215921-86-1P
 215921-87-2P 215922-00-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 250371-20-1 CAPLUS
 CN Cyclopenta[b]pyrrole-1(2H)-ethanethiol, hexahydro-.beta.-methyl-.alpha.-phenyl-, [(1.alpha.R.,2.beta.S,3.alpha.S,6.alpha.S)-(9CI)] (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).


 REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)


BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of aryloxybenzenesulfonylhydroxycarboxamides as metalloproteinase inhibitors)
 RN 215921-66-7 CAPLUS
 CN Butanamide,
 2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[[[5-methyl-3-isoxazolyl)methyl]thio]-, (2S,3R)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 215921-67-8 CAPLUS
 CN Butanamide,
 2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[(2-pyridinylmethyl)thio]-, (2S,3R)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 215921-68-9 CAPLUS
 CN Butanamide,
 2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[[[1-methyl-1H-imidazol-2-yl)methyl]thio]-, (2S,3R)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 215921-69-0 CAPLUS
 CN Butanamide,
 2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-

Absolute stereochemistry.




RN 215921-70-3 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenoxy)phenyl]sulfonyl]methylamino]-3-[[2-[(dimethylamino)ethyl]thio]-N-hydroxy-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215921-83-8 CAPLUS
CN Butanamide, 2-[[[(4-fluorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[[5-methyl-3-isoxazolyl]methyl]thio]-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215921-84-9 CAPLUS
CN Butanamide, 2-[[[(4-fluorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[[2-pyridinylmethyl]thio]-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215922-00-2 CAPLUS
CN Butanamide, N-hydroxy-3-[[5-methyl-3-isoxazolyl]methyl]thio]-2-[[methyl[(4-pyridinyl)oxy]phenyl]sulfonyl]amino]-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 215921-85-0 CAPLUS
CN Butanamide, 2-[[[(4-fluorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-3-[[[(1-methyl-4-piperidinyl)methyl]thio]-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215921-86-1 CAPLUS
CN Butanamide, 3-[[2-[(dimethylamino)ethyl]thio]-2-[[[(4-fluorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215921-87-2 CAPLUS
CN Butanamide, 3-[[2-[(dimethylamino)ethyl]thio]-2-[[[(4-fluorophenoxy)phenyl]sulfonyl]methylamino]-N-hydroxy-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 1998:693417 CAPLUS
DOCUMENT NUMBER: 129:343326
TITLE: Preparation of benzenes as protein kinase C inhibitors
INVENTOR(S): Mori, Toyoki; Tomimaga, Michiaki; Tabusa, Fujio; Ei, Kazuyoshi; Nakaya, Kenji; Takemura, Isao; Shinohara, Tomokazu; Tanada, Yoshihisa; Yamauchi, Takahito; Kitano, Kazuyoshi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 359 pp.
CODEN: JKXKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10287634	A2	19981027	JP 1997-110527	19970411
PRIORITY APPL. INFO.:			JP 1997-110527	19970411
OTHER SOURCE(S):		MARPAT 129:343326		




AB Benzenes I [R1 = 5- to 6-membered (un)substituted unsatd. heterocyclyl having 1-4 N, O, or S; cyano, carboxyalkyl, alkoxy, carbonyl, H, Bz, (un)substituted amido, etc.; R2 = (un)substituted Bz, (un)substituted 1,2,3,4-tetrahydroquinolinyl, pyridyl, (un)substituted lower alkythio, cycloalkylthio, cyano, etc.; R3 = H, lower alkyl, PhS, (un)substituted lower alkyl, lower alkoxy, (un)substituted aminoalkylene, (un)substituted aminoalkylenoxy; R4 = substituted alkenyl, phenylthio, ureidocarbonyl, pyrimidinyl, carbonylalkoxy, etc.; n = 1-3; the dot line may be double bond] or their salts are prepd. I are useful for prevention and treatment of chronic rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, heart failure, allergy, multiple sclerosis, tumor, Alzheimer-type dementia, etc. Condensation of 250 mg 2-(benzylmethyl)pyridine with 300 mg 4-[[2-benzothiazolyl]aminocarbonyl]benzaldehyde in C6H6 for 10 h gave 0.3 g 2-[[2-benzoyl-2-(2-pyridyl)vinyl]benzylamino]benzothiazole.
IT 215506-65-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of benzenes as protein kinase C inhibitors for treatment of diseases)

L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 215506-65-3 CAPLUS

CN Benzamide,

N-2-benzothiazolyl-4-[(1-ethylthio)-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



IT 215504-20-4P 215506-70-0P 215506-71-1P

215506-72-2P 215506-74-4P 215506-80-2P

215506-87-9P 215506-89-1P 215506-91-5P

215506-92-6P 215506-98-2P 215506-99-3P

215507-00-9P 215507-02-1P 215507-03-2P

215507-04-3P 215507-07-6P 215507-08-7P

215507-09-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzene as protein kinase C inhibitors for treatment of diseases)

RN 215504-20-4 CAPLUS

CN

Benzoic acid, 5-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-3-(ethylthio)-1-oxo-2-(1H-1,2,4-triazol-1-yl)propyl]-2-(methoxymethoxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 215506-70-0 CAPLUS

CN

2-Propenamide, N-2-benzothiazolyl-3-[4-[(1-ethylthio)-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215506-80-2 CAPLUS

CN


2-Propenamide, N-2-benzothiazolyl-3-[4-[(1-ethylthio)-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)



RN 215506-87-9 CAPLUS

CN

2-Propenamide, N-2-benzothiazolyl-3-[4-[(1-ethylthio)-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 215506-89-1 CAPLUS

CN

Ethanethioic acid, S-[1-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl] ester (9CI) (CA INDEX NAME)


L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215506-71-1 CAPLUS

CN


Benzoic acid, 5-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215506-72-2 CAPLUS

CN

Acetic acid, 1-[1-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]thio]- (9CI) (CA INDEX NAME)




RN 215506-74-4 CAPLUS

CN

Benzoic acid, 5-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215506-91-5 CAPLUS

CN


Benzoic acid, 5-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215506-92-6 CAPLUS

CN


Benzoic acid, 5-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215506-98-2 CAPLUS


CN

Benzoic acid, 5-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 215506-99-3 CAPLUS
CN 2-Propenamide, N-2-benzothiazolyl-3-[4-[1-[(1,1-dimethylethyl)thio]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 215507-00-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[(2-(diethylamino)ethyl)thio]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215507-02-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(ethylthio)-3-oxo-3-(3-pyridinyl)-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 215507-03-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[(2-hydroxyethyl)thio]-3-oxo-3-(3-pyridinyl)-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 215507-09-8 CAPLUS
CN Cysteine, S-[1-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215507-04-3 CAPLUS
CN 2-Propenamide, N-2-benzothiazolyl-3-[4-[1-(ethylthio)-3-oxo-3-(3-pyridinyl)-2-(1H-1,2,4-triazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 215507-07-6 CAPLUS
CN 2-Propenamide, N-2-benzothiazolyl-3-[4-[1-[(2-hydroxyethyl)thio]-3-oxo-3-(3-pyridinyl)-2-(1H-1,2,4-triazol-1-yl)propyl]phenyl]- (9CI) (CA INDEX NAME)



RN 215507-08-7 CAPLUS
CN 2-Propenamide, N-2-benzothiazolyl-3-[4-[1-[(2-(diethylamino)ethyl)thio]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:632164 CAPLUS
DOCUMENT NUMBER: 129:343594
TITLE: Structural chemistry of methyl- and allylpalladium(II)
AUTHOR(S): complexes containing chiral thioether auxiliaries Boog-Wick, Karin; Pregosin, Paul S.; Woerle, Michael; Albinati, Alberto
CORPORATE SOURCE: Lab. Anorganische Chem., ETH Zentrum Zuerich, Zurich, CH-8092, Switz.
SOURCE: Helvetica Chimica Acta (1998), 81(9), 1622-1633
CODEN: HCACAV; ISSN: 0018-019X
PUBLISHER: Verlag Helvetica Chimica Acta AG
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:343594
AB The synthesis and mol. structures of two [PdCl(Me)] complexes each contg. a different chiral N,S-chelate based on {(dihydrooxazolyl)phenyl)methyl}t hioglucose backbones, i.e., chloro[(2-[(4S)-4,5-dihydro-4-isopropylloxazol-2-yl-.kappa.N]phenyl)methyl 2,3,4,6-tetra-O-acetyl-1-(thio-.kappa.S)-.beta.-D-glucopyranoside)methylpalladium(II)] and a [Pd(.eta.3-C3H5)(PS)]+ cation in which the P,S-chelate stems from a phosphinoferrocene and thioephedrine-derived thioether donor as well as [(S)-1-(diphenylphosphino-.kappa.P)-2-[(1R)-1-[(1R,2S)-1-phenyl-2-(piperidin-1-yl)propyl]thio-.kappa.S]ethyl)ferrocene](.eta.3-prop-2-enyl)palladium trifluoromethanesulfonate are reported. In the methylpalladium compd. the thioglucose-.kappa.S moiety is pseudo-axial, whereas in the allyl complex, the thioephedrine-.kappa.S moiety is markedly pseudo-equatorial. It is suggested, based on these results, that the shape (chiral pocket) of such coordinated chiral thioethers may not be readily predictable.
IT 215027-87-SP
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of methyl- and allylpalladium complexes with chiral thioether moieties)
RN 215027-87-5 CAPLUS
CN Ferrocene, 1-(diphenylphosphino)-2-[(1R)-1-[(1R,2S)-1-phenyl-2-(1-piperidinyl)propyl]thio]ethyl]-, (1R)- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1998:613769 CAPLUS
 DOCUMENT NUMBER: 129:298374
 TITLE: Antibacterial and antifungal peptide from Dolabella auricularia
 INVENTOR(S): Yamazaki, Masatoshi; Iijima, Ryosuke; Kosuna, Kenichi
 PATENT ASSIGNEE(S): Amino Atsupu Kagaku K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10251297	A2	19980922	JP 1997-54435	19970310
JP 1997-54435				19970310

PRIORITY APPL. INFO.:

AS New peptide, dolabellamin B2.

SeqHisGlnAspCysTyrGluAlaLeuHisLysCysMetAlaSer,

isolated from exts. of Dolabella auricularia exhibits antifungal and antibacterial activities.

IT 214596-09-5P, Dolabellamin B2

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)

(antibacterial and antifungal peptide from Dolabella auricularia)

RN 214596-09-5 CAPLUS

CN L-Glutamine, L-seryl-L-histidyl-L-glutamyl-L- α -aspartyl-L-cysteinyl-L-tyrosyl-L- α -glutamyl-L-alanyl-L-leucyl-L-histidyl-L-

lysyl-L-cysteinyl-L-methionyl-L-alanyl-L-seryl-L-histidyl-L-seryl-L-lysyl-

L-prolyl-L-phenylalanyl-L-seryl-L-cysteinyl-L-seryl-L-methionyl-L-lysyl-L-phenylalanyl-L-histidyl-L-methionyl-L-cysteinyl-L-leucyl-L-glutamyl-L-glutamyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> fil stnguide
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
82.97	237.63

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-12.37	-12.37

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 13:59:02 ON 22 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 16, 2003 (20030516/UP).

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.48	238.11

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-12.37

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:04:06 ON 22 MAY 2003